Adynxx
OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
LifePoint
OTCMKTS:LFPILifePoint, Inc. develops, manufactures, and sells IMPACT Test System, a diagnostic testing and screening device. It serves workplaces, ambulances, pharmacies, law enforcements, and home health care markets. LifePoint, Inc. was formerly known as US Drug Testing, Inc. and changed its name to LifePoint, Inc. in February 1998. The company was incorporated in 1992 and is based in Ontario, California.
Nuvectra
OTCMKTS:NVTRQNuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Oncologix Tech
OTCMKTS:OCLGOncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.
Valeritas
OTCMKTS:VLRXQValeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.